Compare State Street SPDR S&P Biotech ETF (XBI) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs Financial Select Sector SPDR Fund — how do they compare? State Street SPDR S&P Biotech ETF trades at $153.76 (market cap $10.11B), while Financial Select Sector SPDR Fund trades at $54.8 (market cap $50.06B). The key difference: Financial Select Sector SPDR Fund is far larger — about 5× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Financial Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR S&P Biotech ETF for 38 Days and Financial Select Sector SPDR Fund for 104 Days on average.
| XBI | XLF | |
|---|---|---|
Market Cap | $10.11B | $50.06B |
Volume | 12,903,266 | 47,464,120 |
Sector | Broad Market / Factor | — |
52-Week High | $169.55 | $58.55 |
52-Week Low | $104.99 | $47.80 |
Typical Hold Time | 38 Days | 104 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
XLF trades at $54.71, up 1.78% with a bearish technical signal from moving averages. The ETF faces sector headwinds as financial stocks lag the S&P 500 by the widest margin since 1990 despite rising bank profits. Recent Fed stress test changes and interest rate hikes create both opportunities and volatility for financial sector holdings.
Financial sector exposure benefits from rising interest rates but faces regulatory uncertainty and market underperformance risks. The divided Congress outlook suggests limited major legislation, maintaining sector-specific policy focus. XLF's concentrated 76-holding portfolio offers large-cap financial exposure with competitive 0.08% expense ratio.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
